Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03305146 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Feasibility of Molecular Biology in Pancreatic Cyst Tumors

Study acronym: CYST-GEN
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 120 to confirmed 93
    • Study completion date: Jan 2022 to Jan 2027
    • Site details revised at 11 of 11 sites
    v3
  2. Study sites: 4 to 11
    • Primary completion date changed from estimate of Jan 2019 to Dec 2017
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of the study is to compare the diagnostic accuracy of intra-cystic fluid DNA molecular analysis to standard diagnostics. The secondary objective of the study is to evaluate the feasibility of intra-cystic fluid DNA molecular analysis.
Trial Details
NCT Number NCT03305146
Lead Sponsor Hospital St. Joseph, Marseille, France
Collaborators: GCS Ramsay Santé pour l'Enseignement et la Recherche
Conditions
(from sponsor)		 Pancreatic Cyst, Pancreas Cyst, Serous Cystadenoma, Mucinous Cystadenoma, IPMN
Related terms Cystadenoma, Mucinous, Cystadenoma, Serous, Pancreatic Cyst
Enrollment 93 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov